Vaxcyte (PCVX) PT Raised to $163 at Mizuho

Mizuho analyst Salim Syed raised the price target on Vaxcyte (NASDAQ: PCVX) to $163.00 (from $113.00) while maintaining a Outperform rating.

The analyst commented: "We are updating our PCVX model post the positive Ph1/2 top-line readout of VAX-31 in adults. We maintain an Outperform rating and increase our PT from $113 to $163. Please email us for a copy of our updated model in Excel, if you'd like it."

You May Also Be Interested In

• Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
• H.C. Wainwright Reiterates Buy Rating on Celcuity Inc (CELC)
• Intuit (INTU) PT Lowered to $430 at Mizuho